Safety and Pharmacokinetics of Rising Doses of APO010 in Relapsed/Refractory Multiple Myeloma Patients Selected by DRP

NCT03196947 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

1

Enrollment

INDUSTRY

Sponsor class

Stopped The study was terminated early due to sponsors decision

Conditions

Relapsed/Refractory Multiple Myeloma

Interventions

DRUG: APO010

Sponsor

Allarity Therapeutics

Collaborators

[object Object]
[object Object]